Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside.

Julien Fleurence,Sophie Fougeray,Lisa Oliver,François Vallette,Delphine Loussouarn,Mickaël Terme,Stéphane Birklé,Mylène Dorvillius,François Paris,Fanny Geraldo,Denis Cochonneau

doi:10.18632/oncotarget.9226

Abstract

There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.

Highlights

Glioblastoma multiforme (GBM, WHO grade IV) is the most common primary brain tumor and it is invariably fatal [1]
Ganglioside OAcGD2 is expressed on human glioblastoma
These results show that expression of OAcGD2 can serve as a marker of glioblastoma

Summary

Introduction

Glioblastoma multiforme (GBM, WHO grade IV) is the most common primary brain tumor and it is invariably fatal [1]. New effective strategies that can eliminate the residual tumor cells are urgently needed. Immunotherapy offers a precise approach for targeting residual glioblastoma cells with reduced risk of collateral toxicity [5]. This property gives them the capacity for immune escape, with the subsequent highrisk of recurrence of antigen-negative tumors [8]. Given these limitations, the identification of new tumor-specific antigens is necessary

Methods

Results

Conclusion